<?xml version='1.0' encoding='utf-8'?>
<document id="24915025"><sentence text="Profound reduction in the tamoxifen active metabolite endoxifen in a patient on phenytoin for epilepsy compared with a CYP2D6 genotype matched cohort."><entity charOffset="26-35" id="DDI-PubMed.24915025.s1.e0" text="tamoxifen" /><entity charOffset="80-89" id="DDI-PubMed.24915025.s1.e1" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.24915025.s1.e0" e2="DDI-PubMed.24915025.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24915025.s1.e0" e2="DDI-PubMed.24915025.s1.e1" /></sentence><sentence text="Tamoxifen is a prodrug, requiring cytochrome P450 enzyme-mediated metabolism to form the active metabolite endoxifen"><entity charOffset="0-9" id="DDI-PubMed.24915025.s2.e0" text="Tamoxifen" /></sentence><sentence text=" We identified a case of drug-drug interaction involving tamoxifen and phenytoin, associated with a markedly lower endoxifen level than predicted"><entity charOffset="57-66" id="DDI-PubMed.24915025.s3.e0" text="tamoxifen" /><entity charOffset="71-80" id="DDI-PubMed.24915025.s3.e1" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.24915025.s3.e0" e2="DDI-PubMed.24915025.s3.e0" /><pair ddi="false" e1="DDI-PubMed.24915025.s3.e0" e2="DDI-PubMed.24915025.s3.e1" /></sentence><sentence text=" The patient is a 49-year-old woman, genotyped as a cytochrome P450 2D6 (CYP2D6) extensive metabolizer, chronically taking phenytoin for a seizure disorder"><entity charOffset="123-132" id="DDI-PubMed.24915025.s4.e0" text="phenytoin" /></sentence><sentence text=" The plasma endoxifen level 2 months after starting tamoxifen was 4"><entity charOffset="52-61" id="DDI-PubMed.24915025.s5.e0" text="tamoxifen" /></sentence><sentence text="72 nmol/l, the lowest level we have seen in our clinic among patients with CYP2D6 extensive metabolizer genotypes (n=195)" /><sentence text=" To our knowledge, this is the first report documenting the extent of induction in terms of both tamoxifen and endoxifen levels during concomitant phenytoin therapy, and this effect would likely result in loss of therapeutic benefit from tamoxifen"><entity charOffset="97-106" id="DDI-PubMed.24915025.s7.e0" text="tamoxifen" /><entity charOffset="111-120" id="DDI-PubMed.24915025.s7.e1" text="endoxifen" /><entity charOffset="147-156" id="DDI-PubMed.24915025.s7.e2" text="phenytoin" /><entity charOffset="238-247" id="DDI-PubMed.24915025.s7.e3" text="tamoxifen" /><pair ddi="false" e1="DDI-PubMed.24915025.s7.e0" e2="DDI-PubMed.24915025.s7.e0" /><pair ddi="false" e1="DDI-PubMed.24915025.s7.e0" e2="DDI-PubMed.24915025.s7.e1" /><pair ddi="false" e1="DDI-PubMed.24915025.s7.e0" e2="DDI-PubMed.24915025.s7.e2" /><pair ddi="false" e1="DDI-PubMed.24915025.s7.e0" e2="DDI-PubMed.24915025.s7.e3" /><pair ddi="false" e1="DDI-PubMed.24915025.s7.e1" e2="DDI-PubMed.24915025.s7.e1" /><pair ddi="false" e1="DDI-PubMed.24915025.s7.e1" e2="DDI-PubMed.24915025.s7.e2" /><pair ddi="false" e1="DDI-PubMed.24915025.s7.e1" e2="DDI-PubMed.24915025.s7.e3" /><pair ddi="false" e1="DDI-PubMed.24915025.s7.e2" e2="DDI-PubMed.24915025.s7.e2" /><pair ddi="false" e1="DDI-PubMed.24915025.s7.e2" e2="DDI-PubMed.24915025.s7.e3" /></sentence><sentence text=" Phenytoin should therefore not be used concurrently with tamoxifen for extended periods of time unless a therapeutic drug (endoxifen) monitoring strategy is utilized"><entity charOffset="58-67" id="DDI-PubMed.24915025.s8.e0" text="tamoxifen" /></sentence><sentence text=" " /></document>